Hims & Hers CEO Targets Peptides to Extend GLP-1-Fueled Healthcare Push

1 articles · Updated · The Washington Post · May 24

Andrew Dudum is preparing Hims & Hers’s next expansion beyond compounded weight-loss drugs, aiming at peptides and other wellness products tied to longevity.
That push builds on the company’s playbook of using telehealth and internet mass marketing to sell popular prescription treatments directly to consumers.
A factory in Silicon Valley is emerging as part of the effort, signaling a more developed infrastructure behind Dudum’s plan to reshape how Americans access care.
The strategy widens Hims & Hers’s focus from the GLP-1 boom toward a broader wellness-and-longevity business, extending its challenge to traditional healthcare channels.

After lawsuits over weight-loss drugs, is the company's pivot to longevity peptides a smart move or a riskier gamble?

Can a marketing-first company safely sell the promise of longevity with scientifically unproven peptides?